earningsconfidence high
Mereo BioPharma Q1 2026 net loss $6.7M; setrusumab regulatory dialogue initiated for pediatric OI
Mereo BioPharma Group plc
2026-Q1 EPS reported
-$0.01
- Net loss $6.7M vs $12.9M YoY; cash $36.2M as of March 31, expected runway into mid-2027.
- Setrusumab Phase 3 studies missed primary fracture endpoint but achieved significant bone mineral density and PRO improvements; regulatory engagement for pediatric OI started.
- Alvelestat partnership discussions ongoing; single Phase 3 trial (~220 patients) could start within 6 months of deal.
- Vantictumab Phase 2 in osteopetrosis expected H2 2026 by partner āshibio; Mereo retains European rights.
- R&D expenses $4.7M (+$0.8M YoY) driven by setrusumab manufacturing costs; G&A $4.0M (-$3.3M) due to ADR reimbursement and savings.
item 2.02item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.